<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="965">
  <stage>Registered</stage>
  <submitdate>9/11/2005</submitdate>
  <approvaldate>9/11/2005</approvaldate>
  <nctid>NCT00251940</nctid>
  <trial_identification>
    <studytitle>GALLANT 7 Tesaglitazar Add-on to Sulphonylurea</studytitle>
    <scientifictitle>A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Sulphonylurea Alone</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EudraCT No 2004-001144-71</secondaryid>
    <secondaryid>D6160C00032</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Tesaglitazar 0.5 or 1 mg
Treatment: drugs - Glibenclamide 2.5, 5, 10 or 15 mg

Treatment: drugs: Tesaglitazar 0.5 or 1 mg


Treatment: drugs: Glibenclamide 2.5, 5, 10 or 15 mg


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c)</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in the following variables from baseline to the end of the randomized treatment period:</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> The change in fasting plasma glucose (FPG), insulin, proinsulin and C-peptide</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Insulin sensitivity by assessment of change in the calculated variable homeostasis assessment model</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Lipid parameters (triglyceride [TG], total cholesterol, high-density lipoprotein cholesterol [HDL C], non-HDL C, low-density lipoprotein cholesterol [LDL C], apolipoproteins [Apo] A-I, Apo B, Apo CIII, free fatty acids, lipoprotein particle size and c</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> C-reactive protein, LDL C/HDL C ratio and Apo B/Apo A-I ratio</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> FPG, homeostasis assessment model, insulin, proinsulin, C-peptide</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Tumor necrosis factor-alpha, intracellular adhesion molecule-1</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Fibrinogen</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Urinary albumin excretion</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Waist/hip ratio</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Responder analyses for HbA1c, FPG, TG, HDL C, total cholesterol, non HDL C and LDL C according to pre-specified values</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Proportion of patients reaching pre-specified target levels for HbA1c, FPG, TG, HDL C, non-HDL C and LDL C</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Pharmacokinetics of tesaglitazar</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Provision of a written informed consent

          -  Female patients: postmenopausal, hysterectomized, or if of childbearing potential,
             using a reliable method of birth control

          -  Diagnosed with type 2 diabetes

          -  Treated with diet alone or treatment with a single oral antidiabetic agent or low
             doses of two oral antidiabetic agents</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Type 1 diabetes

          -  New York Heart Association heart failure Class III or IV

          -  Treatment with chronic insulin

          -  History of hypersensitivity or intolerance to any peroxisome proliferator-activated
             receptor agonist (like Actos or Avandia), fenofibrate, metformin or
             3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)

          -  History of drug-induced myopathy or drug-induced creatine kinase elevation, liver
             enzyme elevations, neutropenia (low white blood cells)

          -  Creatinine levels above twice the normal range

          -  Creatine kinase above 3 times the upper limit of normal

          -  Received any investigational product in other clinical studies within 12 weeks

          -  Any clinically significant abnormality identified on physical examination, laboratory
             tests or electrocardiogram, which in the judgment of the investigator would compromise
             the patient's safety or successful participation in the clinical study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - Adelaide</hospital>
    <hospital>Research Site - Brisbane</hospital>
    <hospital>Research Site - Cairns</hospital>
    <hospital>Research Site - Geelong</hospital>
    <hospital>Research Site - Melbourne</hospital>
    <hospital>Research Site - Perth</hospital>
    <hospital>Research Site - Sydney</hospital>
    <hospital>Research Site - Tasmania</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Cairns</postcode>
    <postcode> - Geelong</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Perth</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Tasmania</postcode>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Angers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Hyeres</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Garde</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Seyne Sur Mer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Laval</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Brusc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Lavandou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montrevault</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Cyr</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Six Fours Les Plages</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tierce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ashkelon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Holon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Rishon-Lezion</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Zefat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Suwon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Bergen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Elverum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Enebakk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Fredrikstad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Gamle Fredrikstad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Hamar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Haugesund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Hurdal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Inderøy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Lena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Levanger</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Rud</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Sedsmokorset</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Soerumsand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Stavanger</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Manila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Marikina City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Pasig City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Chatsworth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alzira (Valencia)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Guissona (Lleida)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>San Sebastian de los Reyes ( Madrid)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>San Vicente de Raspeig (Alicante)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Ireland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Aberdeen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Barnsley</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bath</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Belfast</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Coventry</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dundee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>East Sussex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Shrewsbury</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Surrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Midlands</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wiltshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wrexham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Vietnam</country>
      <state>Hanoi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Vietnam</country>
      <state>Ho Chi Minh</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a 24-week randomized double-blind, parallel-group, multi-center, placebo-controlled
      study of tesaglitazar (0.5 mg and 1 mg) given as add-on therapy to sulphonylurea in patients
      with type 2 diabetes, not adequately controlled on optimized sulphonylurea treatment and on
      diet/lifestyle advice during the titration and run-in period. The study comprises a 2-week
      enrollment period, 6 week placebo metformin titration period, 2-week single-blind run-in
      period, followed by a 24-week double blind treatment period and a 3-week follow-up period</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00251940</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>AstraZeneca Galida Medical Science Director, MD</name>
      <address>AstraZeneca</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>